Virax Biolabs Group (NASDAQ:VRAX) Shares Down 5.3% – What’s Next?

Virax Biolabs Group Limited (NASDAQ:VRAX)’s stock price traded down 5.3% on Friday . The company traded as low as $0.21 and last traded at $0.2130. 93,300 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 183,739 shares. The stock had previously closed at $0.2250.

Analyst Ratings Changes

VRAX has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Friday, January 9th. Zacks Research raised shares of Virax Biolabs Group to a “hold” rating in a research report on Tuesday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $1.00 target price (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Stock Down 5.3%

The business’s fifty day moving average is $0.31 and its 200-day moving average is $0.49.

Virax Biolabs Group (NASDAQ:VRAX) last announced its earnings results on Tuesday, December 2nd. The company reported ($0.27) EPS for the quarter. The business had revenue of $0.00 million for the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.